Characterization of glioma stem-like cells from human glioblastomas

Yamamuro,Shun; Okamoto,Yutaka; Sano,Emiko; Ochiai,Yushi; Ogino,Akiyoshi; Ohta,Takashi; Hara,Hiroyuki; Ueda,Takuya; Nakayama,Tomohiro; Yoshino,Atsuo; Katayama,Yoichi

doi:10.3892/ijo.2015.2992

Characterization of glioma stem-like cells from human glioblastomas

Authors:
- Shun Yamamuro
- Yutaka Okamoto
- Emiko Sano
- Yushi Ochiai
- Akiyoshi Ogino
- Takashi Ohta
- Hiroyuki Hara
- Takuya Ueda
- Tomohiro Nakayama
- Atsuo Yoshino
- Yoichi Katayama
View Affiliations

Affiliations: Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan, New Energy and Industrial Technology Development Organization, Kanagawa, Japan, Department of Medical Genome Sciences, Graduate School of Frontier Science, The University of Tokyo, Chiba, Japan, Department of Functional Morphology, Nihon University School of Medicine, Tokyo, Japan, Division of Companion Diagnostics, Department of Pathology of Microbiology, Nihon University School of Medicine, Tokyo, Japan
Published online on: May 7, 2015 https://doi.org/10.3892/ijo.2015.2992
Pages: 91-96
Copyright: © Yamamuro et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma stem-like cells (GSCs) could have potential for tumorigenesis, treatment resistance, and tumor recurrence (GSC hypothesis). However, the mechanisms underlying such potential has remained elusive and few ultrastructural features of the cells have been reported in detail. We therefore undertook observations of the antigenic characteristics and ultrastructural features of GSCs isolated from human glioblastomas. Tumor spheres formed by variable numbers of cells, exhibiting a variable appearance in both their size and shape, were frequently seen in GSCs expressing the stem cell surface markers CD133 and CD15. Increased cell nucleus atypia, mitochondria, rough endoplasmic reticulum, coated vesicles, and microvilli, were noted in the GSCs. Furthermore, cells at division phases and different phases of the apoptotic process were occasionally observed. These findings could imply that GSCs have certain relations with human neural stem cells (NSCs) but are primitively different from undifferentiated NSCs. The data may provide support for the GSC hypothesis, and also facilitate the establishment of future glioblastoma treatments targeting GSCs.

View Figures

View References

1	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
2	Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, Kato T, Chansakul P, Ito M, Kim SU and Wakabayashi T: Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett. 284:71–79. 2009. View Article : Google Scholar : PubMed/NCBI
3	Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
4	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar
7	Zhao Y, Huang Q, Zhang T, Dong J, Wang A, Lan Q, Gu X and Qin Z: Ultrastructural studies of glioma stem cells/progenitor cells. Ultrastruct Pathol. 32:241–245. 2008. View Article : Google Scholar
8	Yang B, Wang Y, Yang C, Ouyang W, Zhou F, Zhou Y and Xie C: The ultrastructural difference between CD133-positive U251 glioma stem cells and normal U251 glioma cells. Ultrastruct Pathol. 36:404–408. 2012. View Article : Google Scholar : PubMed/NCBI
9	Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, et al: Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 31:2715–2724. 2012. View Article : Google Scholar
10	Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E, et al: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
11	He J, Shan Z, Li L, Liu F, Liu Z, Song M and Zhu H: Expression of glioma stem cell marker CD133 and O⁶-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol Rep. 26:1305–1313. 2011.PubMed/NCBI
12	Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
13	Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S and Lee MC: The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology. 31:494–502. 2011. View Article : Google Scholar : PubMed/NCBI
15	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
16	Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG and Karayan-Tapon L: O⁶-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci. 13:6983–6994. 2012. View Article : Google Scholar
17	Dimov I, Tasić-Dimov D, Conić I and Stefanovic V: Glioblastoma multiforme stem cells. Sci World J. 11:930–958. 2011. View Article : Google Scholar
18	Jin X, Jin X, Jung JE, Beck S and Kim H: Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun. 433:496–501. 2013. View Article : Google Scholar : PubMed/NCBI
19	Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
21	Pavon LF, Marti LC, Sibov TT, Malheiros SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E and Gamarra LF: The ultrastructural study of tumorigenic cells using nanobiomarkers. Cancer Biother Radiopharm. 25:289–298. 2010. View Article : Google Scholar : PubMed/NCBI
22	Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, Fei Z, Zhen HN, You SW and Yang H: Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol. 2:247–257. 2009. View Article : Google Scholar : PubMed/NCBI
23	Capela A and Temple S: LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron. 35:865–875. 2002. View Article : Google Scholar : PubMed/NCBI
24	Son MJ, Woolard K, Nam DH, Lee J and Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4:440–452. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zhang QB, Ji XY, Huang Q, Dong J, Zhu YD and Lan Q: Differentiation profile of brain tumor stem cells: A comparative study with neural stem cells. Cell Res. 16:909–915. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lobo MV, Alonso FJ, Redondo C, López-Toledano MA, Caso E, Herranz AS, Paíno CL, Reimers D and Bazán E: Cellular characterization of epidermal growth factor-expanded free-floating neurospheres. J Histochem Cytochem. 51:89–103. 2003. View Article : Google Scholar
27	Arum CJ, Anderssen E, Viset T, Kodama Y, Lundgren S, Chen D and Zhao CM: Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: A study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia. 12:434–442. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zaguia F and Schneider R: Microvilli expressed on glioma cells keep cytotoxic cells at a distance. Cancer Biol Ther. 11:1–3. 2011. View Article : Google Scholar
29	Gritti A, Vescovi AL and Galli R: Adult neural stem cells: Plasticity and developmental potential. J Physiol Paris. 96:81–90. 2002. View Article : Google Scholar : PubMed/NCBI
30	Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI